Enterprise Value
5.718B
Cash
434.9M
Avg Qtr Burn
-131.9M
Short % of Float
13.34%
Insider Ownership
5.37%
Institutional Own.
92.15%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details Molybdenum cofactor deficiency type A | Approved Quarterly sales | |
Acoramidis (AG10) Details Transthyretin Amyloid Cardiomyopathy | PDUFA Approval decision | |
Infigratinib Details Achondroplasia | Phase 3 Data readout | |
Phase 3 Data readout | ||
BBP-418 Details Limb-Girdle Muscular Dystrophy | Phase 3 Data readout | |
BBP-398 + OPDIVO Details Solid tumor/s, Lung cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
BBP-631 Details Congenital adrenal hyperplasia | Phase 1/2 Update | |
BBP- 812 Details Canavan disease | Phase 1/2 Update | |
TRUSELTIQ (infigratinib) Details Cholangiocarcinoma | Failed Discontinued |